Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

IM2PACT

Financiado

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics...

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics IM2PACT Into The Brain The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the ide... ver más

31/12/2024

UOXF

17M€

Presupuesto del proyecto: 17M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 30 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-14

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

IMI2-2017-12-06: Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases

I+D

Cerrada hace 7 años

0% 100%

30 Participantes

UOXF

2.18M€ | Lider

NOVARTIS FARMACEUTICA

646.21K€ | Participante

UNIMORE

67.57K€ | Participante

JANSSEN PHARMACEUTICA NV

1.10M€ | Participante

Proyectos interesantes

HumBrain Computational modelling of the human brain lipidome 207K€ Cerrado

EIN2020-112381 MODELIZACION DE ENFERMEDADES NEURODEGENERATIVAS 15K€ Cerrado

PID2020-115961RB-C31 ESTUDIO EXPERIMENTAL DEL FLUJO DE LIQUIDO CEFALORRAQUIDEO EN... 169K€ Cerrado

DeliChoP Drug DELIvery to the brain via CHOroid Plexus targeting 2M€ Cerrado

AETIONOMY Aetionomy – Organising Mechanistic Knowledge about Neurodege... 18M€ Cerrado

OBGate Creating an orthogonal gate to the brain 1M€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 72 meses Fecha Inicio: 2018-12-14
Fecha Fin: 2024-12-31

Presupuesto del proyecto 17M€

Descripción del proyecto The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease). The related key deliverables will be as follows: 1.Identification and validation of specific genes and/or mechanisms which are altered in brain endothelial cells in disease. 2. Generation, validation and characterisation of robust and predictive iPSC-derived BBB models: The developed models should be more reflective of the in vivo situation than existing models, in the healthy and disease states. 3. New, efficacious and safe mechanisms and technologies of brain delivery: The output of this topic should also result in an expanded and deepened understanding of the fundamental processes that underpin drug-trafficking across the BBB, which in turn can further support endeavours to elucidate novel and more efficacious brain delivery mechanisms. 4. Characterised new genetic models for the diseases of interest in this topic which are better amenable to evaluate disease-modifying agents. 5. Characterised mechanisms of neurotropic virus-mediated BBB and CNS penetration for development of selective brain delivery systems. 6. Established in silico/mathematical models in predicting BBB penetration of therapeutics (such as receptor-or carrier-mediated transcytosis for delivery across the BBB) and pharmacokinetics of biopharmaceutics in different compartments of CNS. 7. Identification of relevant translational readouts which are better amenable to elucidate the role of the BBB in the pathogenesis of neurodegeneration and could eventually lead to new targets for the treatment of the neurovascular causes of the diseases.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores